New lung cancer research finds half of advanced lung cancer patients receive chemotherapy

	Tweet

For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages. Prior population-based studies have shown that only 20 to 30 percent of advanced lung cancer patients receive chemotherapy treatment. These studies have previously relied on the Medicare-linked Surveillance, Epidemiology, and End Results (SEER) database, thus excluding the 30 to 35 percent of lung cancer patients younger than 65 years of age.

Researchers performed a retrospective analysis of patients diagnosed with stage IV NSCLC from 2000 to 2007 at the University of Texas Southwestern Medical Center in Dallas, Texas, and Parkland Health and Hospital System, the safety net hospital for Dallas County. Overall, the findings indicate that for patients with advanced non-small cell lung cancer (NSCLC), chemotherapy was administered to approximately half of all patients—more than twice the rate reported in some earlier studies. In all, 718 patients met criteria, of whom 353 received chemotherapy (49 percent).

Age and insurance type were associated with treatment with chemotherapy; specifically, young patients and those with private health insurance were more likely to receive chemotherapy. Furthermore, median survival for the group which received chemotherapy was 9.2 months, compared with 2.3 months for untreated patients. 

"Most of the SEER studies reported data from the early 1990s. Over the past 10 years, advances in diagnosis, treatment, and supportive care may have expanded the patient population considered for cancer therapy,” explains senior investigator David E. Gerber, MD, of the Harold C. Simmons Cancer Center at the University of Texas Southwestern Medical Center. “Furthermore, physicians may not be aware of the growing evidence in support of chemotherapy for advanced NSCLC. It is hoped that future developments in this field increase not only treatment efficacy but also the proportion of patients able to benefit from them.”

###

Journal of Thoracic Oncology (JTO) – (journals.lww.com/jto)

The JTO is a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. The JTO is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC.org) and emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces.

###

Contact: Kaitlin Doody

202-587-2553
International Association for the Study of Lung Cancer

RELATED STORIES:
Genetic Region Linked to a Five Times Higher Lung Cancer Risk   Lung cancer patients need help to quit smoking   TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer   More signs lung cancer screening could save lives   Lower survival rates of blacks with lung cancer may be explained by access to care   Long-Term Use of Nutrient Supplements May Increase Cancer Risk   Bone drug zoledronic acid may help prevent spread of early lung cancer   Cellular clues to vitamin A resistance in lung cancer   Urine Test May Determine if a Smoker is at Risk for Lung Cancer   Video-assisted thoracic surgery valuable tool in lung cancer screening   Lung cancer death rates in lifelong non-smokers   Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer   Researchers Identify Specific Lung Cancer Susceptibility Gene   New technique detects specific chromosomal damage, may indicate lung cancer risk   Faster Tracking of Lung Tumors May Help Treatment   UT Southwestern research uncovers genetic link between emphysema, lung cancer   Lung cancer pill on NHS in 2007   EU lung cancer down in men, up in women   Researchers Identify Tumor-Suppressor Gene for Lung Cancer   Carotenoid supplements tied to lung cancer risk   Surviving Lung Cancer; New Technique Boasts High Cure Rates, Offers Hope in Place of Surgery   Lung cancer screen: a license to smoke?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]